Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 36Stomach Neoplasms 9Colonic Neoplasms 6Rectal Neoplasms 3Sarcoma 2Carcinoma, Hepatocellular 2Advanced Colorectal Carcinoma 2Unresectable Metastatic Colorectal Cancer 1Platinum Resistant Ovarian Cancer 1Patients With Advanced Metastatic Colorectal Cancer 1Pancreatic Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1NSCLC 1Metastatic Colorectal Adenocarcinoma 1Metastasis Colorectal Cancer 1Lung Neoplasms 1Locally Advanced Rectal Cancer 1Gastric/Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Fruquintinib 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Adenocarcinoma 1Advanced Solid Tumors 1Advanced Pancreatic Carcinoma 1Advanced Gastric Cancer 1

Interventions

zolbetuximab 1trifluridine tipiracil drug combination 1tipiracil 1camrelizumab 1Trifluridine 1Taxes 1Oxaliplatin 1HMPL-013 1Docetaxel 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastric Cancer Adenocarcinoma Metastatic × HMPL-013 × Clear all
NCT07392346 2026-02-11

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Chinese PLA General Hospital

Phase 2 Recruiting
68 enrolled
Gastrointestinal

Gastric Cancer Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡